BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
Weijia WangShanzhi HeWenli ZhangHongyu ZhangVincent M DeStefanoMasayuki WadaKevin PinzGreg DeenerDarshi ShahNabil HagagMin WangMing HongRonghao ZengTing LanYu MaFugui LiYingwen LiangZhencong GuoChanjuan ZouMingxia WangLing DingYupo MaYong YuanPublished in: Annals of the rheumatic diseases (2024)
Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.
Keyphrases
- systemic lupus erythematosus
- open label
- clinical trial
- phase ii
- disease activity
- phase iii
- study protocol
- electronic health record
- phase ii study
- big data
- double blind
- squamous cell carcinoma
- stem cells
- randomized controlled trial
- rheumatoid arthritis
- nk cells
- locally advanced
- rectal cancer
- radiation therapy
- smoking cessation